odatroltide

Odatroltide (LT3001) is a novel synthetic small peptide molecule developed for the treatment of acute ischemic stroke. It acts by promoting local endogenous fibrinolysis—enhancing plasminogen binding to fibrin clots and facilitating its activation to plasmin—thereby restoring blood vessel patency. In addition to its thrombolytic effect, odatroltide exhibits neuroprotective properties by scavenging free radicals and reducing inflammation-mediated injury. Preclinical studies have shown that it restores cerebral blood flow and reduces infarct size with a favorable safety profile compared to conventional thrombolytics like rtPA. Clinical trials indicate that intravenous administration of LT3001 improves functional outcomes in stroke patients without increasing the risk of symptomatic intracranial hemorrhage. The drug is being developed by Lumosa Therapeutics and Shanghai Pharmaceutical Group[2][4][5][7].

Other names

odatroltideLT3001 injectionLT-3001 injectionLT 3001 injectionLT3001 drug productLT-3001 drug productLT 3001 drug product